Aptevo Therapeutics Inc. (APVO)

$ 13.07
+1.12 (+9.37%)
Symbol APVO
Price $ 13.07
Beta 6.710
Volume Avg. 3.09M
Market Cap 0.064B
Shares () -
52 Week Range 6.38-51.75
1y Target Est -
DCF Unlevered APVO DCF ->
DCF Levered APVO LDCF ->
ROE -183.90% Strong Sell
ROA -34.67% Strong Sell
Operating Margin -
Debt / Equity 777.74% Strong Buy
P/E -
P/B 8.77 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest APVO news

Mr. Marvin L. White
Nasdaq Global Select

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.